AustinPx, a contract development and manufacturing organization specializing in bioavailability enhancement for orally delivered small molecule drugs, announced the introduction of the KinetiLease™ program, allowing pharmaceutical companies to lease the company’s KinetiSol™ research-scale equipment. This program enables companies to integrate this powerful amorphous dispersion manufacturing tool into their own R&D labs. Additionally, the company has announced the first equipment lease with a top 10 global biotech company.
AustinPx’s KinetiSol Technology is a state-of-the-art manufacturing solution that enables the rapid creation of amorphous solid dispersions (ASD) without the use of solvents, enabling the development of poorly soluble drug molecules, including molecules with high melting points and poor solvent solubility. KinetiSol solid dispersions have been shown to provide increased exposure, improved compressibility, higher ASD loading, and favorable downstream processing characteristics, leading to reduced pill burden.
In the last three years, the KinetiSol Technology has been utilized by global pharmaceutical and biotech companies across more than 60 molecules through AustinPx’s fee-for-service CDMO service offering. Now, companies can access KinetiSol directly in their own R&D laboratories.
Also Read: Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer
“By offering leasing options for KinetiSol equipment, AustinPx is empowering pharmaceutical companies to harness this game-changing technology, rapidly exploring its capabilities across their drug pipeline,” said Elizabeth Hickman, CEO of AustinPx. “We’re excited to offer this technology to our partners, enabling them to advance their drug development efforts and accelerate innovation within their own walls.”
Key features of the KinetiSol Lease Program include:
- Comprehensive training and support
- White glove delivery and installation
- Annual preventative maintenance
AustinPx’s first KinetiSol lease was recently signed with a major global biotech company. Following installation of the equipment, the lease partner received theoretical and operational training. Within two weeks of installation and training, the company began screening small molecule candidates and exploring the technology across multiple programs in their pipeline, including preclinical testing of prototypes.
“We’ve seen firsthand the power of KinetiSol Technology to enhance the solubility of small molecule candidates,” said Chris Brough, co-inventor of KinetiSol Technology and chief technical officer of AustinPx. “After quickly onboarding the technology, our pharma partner achieved solubility enhancement where other methods failed, across multiple molecules. This success showcases KinetiSol’s exceptional capabilities in bioavailability enhancement, formulation flexibility, and speed.”
With its ease of use and small operational footprint, KinetiSol provides a faster, simpler, and more efficient means of producing ASD formulations compared to other technologies. The KinetiLease program offers a practical, flexible alternative for pharmaceutical and biotech companies that are looking to apply this cutting-edge technology directly to their internal development pipelines.
Source: BusinessWire